#49705
Re: Chicharros USA - bolsa internacional
AGEN
Resultados financieros publicados..
- Agenus (NASDAQ: AGEN) reported Q1 EPS of ($0.31), $0.02 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $15.13 million versus the consensus estimate of $12.35 million.
Resultados financieros publicados..
- Agenus (NASDAQ: AGEN) reported Q1 EPS of ($0.31), $0.02 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $15.13 million versus the consensus estimate of $12.35 million.
- AGEN1181 (nextgen CTLA-4) +/- balstilimab (anti-PD-1) shows benefit in 70% of patients in Phase 1
- Balstilimab + Zalifrelimab (anti-CTLA-4) achieve 26% response rates in a cohort of 55 patients with advanced cervical cancer
- Two INDs filed for AgenTus cell therapy (Allogeneic iNKTs) for cancer & COVID-19
- Two TIGIT antibodies advancing; IND filings starting in Q4
- Recent organizational streamlining expected to reduce annualized burn by $50M